Heterozygous Familial Hypercholesterolemia Clinical Trial
Official title:
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03563547 -
Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia
|
N/A | |
| Terminated |
NCT03694197 -
Long Term Safety Study of PRALUENT
|
Phase 4 | |
| Active, not recruiting |
NCT04759534 -
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT00171236 -
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT03397121 -
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 3 | |
| Completed |
NCT04173793 -
A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 2 | |
| Not yet recruiting |
NCT06164730 -
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
|
Phase 1 | |
| Completed |
NCT02326220 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
|
Phase 3 | |
| Completed |
NCT02392559 -
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
|
Phase 3 | |
| Completed |
NCT02460159 -
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
|
Phase 3 | |
| Terminated |
NCT01583647 -
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
|
Phase 1 | |
| Active, not recruiting |
NCT05398029 -
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
|
Phase 1 | |
| Completed |
NCT00706849 -
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
|
Phase 3 | |
| Completed |
NCT04666298 -
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
|
Phase 2 | |
| Completed |
NCT01515241 -
Exploratory Study of Plaque Regression
|
Phase 2 | |
| Completed |
NCT03038022 -
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 2 | |
| Completed |
NCT01576484 -
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 2 | |
| Terminated |
NCT00151788 -
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
|
Phase 2/Phase 3 | |
| Completed |
NCT05325203 -
A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).
|
Phase 3 | |
| Completed |
NCT01709500 -
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
|
Phase 3 |